1. Introduction {#sec1}
===============

Clinicopathologic factors such as histologic type, tumor size, tumor grade, HER-2/*neu*over-expression, hormone receptor status, and lymph node involvement are recognized as having prognostic use in breast cancer management \[[@B3]--[@B6]\]. Collectively assessed, axillary lymph node metastasis is the most important prognostic factor predicting breast cancer patient survival \[[@B7]--[@B9]\]. Currently, the best predictor of axillary lymph node metastasis is the presence or absence of metastasis in the sentinel lymph node.

Current methodologies for this assessment are limited to axillary lymph node dissection and sentinel lymph node biopsy; however, these procedures are not without risks. For example, level I and level II axillary lymph node dissection can be associated with upper extremity lymph edema, wound complications, or nerve injury in a significant proportion of patients. Although sentinel lymph node biopsy is far less morbid than axillary lymph node dissection, it is not without risks or morbidity \[[@B10], [@B11]\]. Sentinel lymph node biopsy, despite its low but measurable false negative rate, provides no information about the presence of additional nonsentinel lymph node metastasis, which may occur in 40% to 70% of cases \[[@B12]--[@B14]\]. As a consequence, newer, more accurate, and less invasive means of predicting axillary lymph node metastasis would greatly improve breast cancer patient management and quality of life.

Morphological mimicry among human malignancies is a well-known histopathological phenomenon \[[@B13]\]. This is especially true in the case of the neoplastic ductal tissues of the breast and the salivary glands where immunostaining revealed the presence of Her2/*neu* (c-*erb*B-2), progesterone receptor, androgen receptor, and GCDFP-15 among these diseased tissues \[[@B13]--[@B16]\]. These studies suggest that similar molecular pathway dysfunctions may also be common within both tissues types \[[@B17]\].

Consequently, research has been performed concerning the presence of cancer related proteins and protein alterations in the secretory by products of these tissues, that is, saliva and nipple aspirate fluid (NAF) \[[@B18], [@B19]\]. Single analyte ELISA-based analyses yielded the presence of soluble Her2/*neu* protein in both saliva and NAF; Her2/*neu* concentrations were found to be elevated in both fluids secondary to the presence of carcinoma of the breast \[[@B18], [@B19]\]. Remarkably, Her2/*neu* protein concentrations were also elevated in the contralateral healthy breast within the same subject. Collectively, this line of research suggests that cancer-related cellular signaling may affect healthy exocrine tissues and result in alterations of their secretory by products. Likewise, EGFR and TNF-*α* were also found to be present in both fluids and altered in the presence of malignant breast disease \[[@B20]\]. Adding further support to this concept, both saliva and NAF were analyzed using mass spectrometry \[[@B21]--[@B23]\]. These fluid analyses yielded striking similarities with respect to their protein profile in health and were altered in the presence of neoplastic disease \[[@B21], [@B23]\].

Capitalizing on the potential of this possible relationship, significant salivary protein profile comparisons and alterations were reported in early stage breast cancer \[[@B23]\]. As a consequence, the purpose of this paper is to report saliva alterations secondary to late stage IDC with a focus concerning lymph node and nonlymph node involvement among the IDC cohorts.

2. Methods {#sec2}
==========

2.1. Design {#sec2.1}
-----------

The investigators protein profiled three pooled, stimulated whole saliva specimens. One specimen consisted of pooled saliva from 10 healthy subjects, another specimen was a pooled saliva specimen from 10 Stage IIa (T~2~N~0~M~0~) invasive ductal carcinoma patients (IDC), and the third pooled specimen was from 10 subjects diagnosed with Stage IIb (T~2~N~1~M~0~) invasive ductal carcinoma \[[@B2]\]. The cancer cohorts were estrogen, progesterone, and Her2/neu receptor status negative as determined by the pathology report. Histological grade was not available for this study. The subjects were matched for age and race and were nontobacco users.

The participating subjects were given an explanation about their participation rights and signed an IRB consent form. The saliva specimens and related patient data are nonlinked and bar coded in order to protect patient confidentiality. This study was performed under the UTHSC IRB approved protocol number HSC-DB-05-0394. All procedures were in accordance with the ethical standards of the UTHSC IRB and with the Helsinki Declaration of 1975, as revised in 1983.

2.2. Saliva Collection and Sample Preparation {#sec2.2}
---------------------------------------------

Stimulated whole salivary gland secretion is based on the reflex response occurring during the mastication of a bolus of food. Usually, a standardized bolus (1 gram) of paraffin or a gum base (generously provided by the Wrigley Co., Peoria, IL) is given to the subject to chew at a regular rate. The individual, upon sufficient accumulation of saliva in the oral cavity, expectorates periodically into a preweighed disposable plastic cup. This procedure is continued for a period of five minutes. The volume and flow rate is then recorded along with a brief description of the specimen\'s physical appearance \[[@B25]\]. The cup with the saliva specimen is reweighed and the flow rate determined gravimetrically. The authors recommend this salivary collection method with the following modifications for consistent protein analyses \[[@B26]\]. A protease inhibitor from Sigma Co (St. Louis, MI, USA) is added along with enough orthovanadate from a 100 mM stock solution to bring its concentration to 1 mM. The treated samples were centrifuged for 10 minutes at top speed in a table top centrifuge. The supernatant was divided into 1 mL aliquots and frozen at −80°C.

2.3. LC-MS/MS Mass Spectroscopy with Isotopic Labeling {#sec2.3}
------------------------------------------------------

Recent advances in mass spectrometry, liquid chromatography, analytical software, and bioinformatics have enabled the researchers to analyze complex peptide mixtures with the ability to detect proteins differing in abundance by over 8 orders of magnitude \[[@B27]\]. One current method is isotopic labeling coupled with liquid chromatography tandem mass spectrometry (IL-LC-MS/MS) to characterize the salivary proteome \[[@B28]\]. The main approach for discovery is a mass spectroscopy-based method that uses isotope coding of complex protein mixtures such as tissue extracts, blood, urine, or saliva to identify differentially expressed proteins \[[@B24]\]. The approach readily identifies changes in the level of expression, thus permitting the analysis of putative regulatory pathways providing information regarding the pathological disturbances in addition to potential biomarkers of disease. The analysis was performed on a tandem QqTOF QStar XL mass spectrometer (Applied Biosystems, Foster City, CA, USA) equipped with an LC Packings (Sunny vale, CA, USA) HPLC for capillary chromatography. The HPLC is coupled to the mass spectrometer by a nanospray ESI head (Protana, Odense, Denmark) for maximal sensitivity \[[@B18]\]. The advantage of tandem mass spectrometry combined with LC is enhanced sensitivity and the peptide separations afforded by chromatography. Thus even in complex protein mixtures MS/MS data can be used to sequence and identify peptides by sequence analysis with a high degree of confidence \[[@B23], [@B27], [@B28], [@B29]\].

Isotopic labeling of protein mixtures has proven to be a useful technique for the analysis of relative expression levels of proteins in complex protein mixtures such as plasma, saliva urine, or cell extracts. There are numerous methods that are based on isotopically labeled protein modifying reagents to label or tag proteins to determine relative or absolute concentrations in complex mixtures. The higher resolution offered by the tandem Qq-TOF mass spectrometer is ideally suited to isotopically labeled applications \[[@B23], [@B28], [@B30], [@B31]\].

Applied Biosystems recently introduced iTRAQ reagents \[[@B28], [@B30], [@B31]\], which are amino reactive compounds that are used to label peptides in a total protein digest of a fluid such as saliva. The real advantage is that the tag remains intact through TOF-MS analysis; however, it is revealed during collision-induced dissociation by MSMS analysis. Thus in the MSMS spectrum for each peptide there is a fingerprint indicating the amount of that peptide from each of the different protein pools. Since virtually all of the peptides in a mixture are labeled by the reaction, numerous proteins in complex mixtures are identified and can be compared for their relative concentrations in each mixture. Thus even in complex mixtures there is a high degree of confidence in the identification.

2.4. Salivary Protein Analyses with iTRAQ {#sec2.4}
-----------------------------------------

Briefly, the saliva samples were thawed and immediately centrifuged to remove insoluble materials. The supernatant was assayed for protein using the Bio-Rad protein assay (Hercules, CA, USA) and an aliquot containing 100 *μ*g of each specimen was precipitated with 6 volumes of −20°C acetone. The precipitate was resuspended and treated according to the manufacturers instructions. Protein digestion and reaction with iTRAQ labels was carried out as previously described and according to the manufacturer\'s instructions (Applied Biosystems, Foster City, CA). Briefly, the acetone precipitable protein was centrifuged in a table---top centrifuge at 15,000 × g for 20 minutes. The acetone supernatant was removed and the pellet resuspended in 20 uL dissolution buffer. The soluble fraction was denatured and disulfides reduced by incubation in the presence of 0.1% SDS and 5 mM TCEP (tris-(2-carboxyethyl) phosphine)) at 60°C for one hour. Cysteine residues were blocked by incubation at room temperature for 10 minutes with MMTS (methyl methane-thiosulfonate). Trypsin was added to the mixture to a protein : trypsin ratio of 10 : 1. The mixture was incubated overnight at 37°C. The protein digests were labeled by mixing with the appropriate iTRAQ reagent and incubating at room temperature for one hour. On completion of the labeling reaction, the four separate iTRAQ reaction mixtures were combined. Since there are a number of components that can interfere with the LCMSMS analysis, the labeled peptides are partially purified by a combination of strong cation exchange followed by reverse phase chromatography on preparative columns. The combined peptide mixture is diluted 10-fold with loading buffer (10 mM KH~2~PO~4~ in 25% acetonitrile at pH 3.0) and applied by syringe to an ICAT Cartridge-Cation Exchange column (Applied Biosystems, Foster City, CA) column that has been equilibrated with the same buffer. The column is washed with 1 mL loading buffer to remove contaminants. To improve the resolution of peptides during LCMSMS analysis, the peptide mixture is partially purified by elution from the cation exchange column in 3 fractions. Stepwise elution from the column is achieved with sequential 0.5 mL aliquots of 10 mM KH2PO4 at pH 3.0 in 25% acetonitrile containing 116 mM, 233 mM, and 350 mM KCl, respectively. The fractions are evaporated by Speed Vac to about 30% of their volume to remove the acetonitrile and then slowly applied to an Opti-Lynx Trap C18 100 uL reverse phase column (Alltech, Deerfield, IL) with a syringe. The column was washed with 1 mL of 2% acetonitrile in 0.1% formic acid and eluted in one fraction with 0.3 mL of 30% acetonitrile in 0.1% formic acid. The fractions were dried by lyophilization and resuspended in 10 uL 0.1% formic acid in 20% acetonitrile. Each of the three fractions was analyzed by reverse phase LCMSMS.

2.5. Reverse Phase LCMSMS {#sec2.5}
-------------------------

The desalted and concentrated peptide mixtures were quantified and identified by nano-LCMS/MS on an API QSTAR XL mass spectrometer (ABS Sciex Instruments) operating in positive ion mode. The chromatographic system consists of an UltiMate nano-HPLC and FAMOS autosampler (Dionex LC Packings). Peptides were loaded on a 75 cm x 10 cm, 3 mm fused silica C18 capillary column, followed by mobile phase elution: buffer (A) 0.1% formic acid in 2% acetonitrile/98% Milli-Q water and buffer (B): 0.1% formic acid in 98% acetonitrile/2% Milli-Q water. The peptides were eluted from 2% buffer B to 30% buffer B over 180 minutes at a flow rate 220 nL/min. The LC eluent was directed to a NanoES source for ESI/MS/MS analysis. Using information-dependent acquisition, peptides were selected for collision induced dissociation (CID) by alternating between an MS (1 second) survey scan and MS/MS (3 seconds) scans. The mass spectrometer automatically chooses the top two ions for fragmentation with a 60-second dynamic exclusion time. The IDA collision energy parameters were optimized based upon the charge state and mass value of the precursor ions. In each saliva sample set there are three separate LCMSMS analyses.

2.6. Bioinformatics {#sec2.6}
-------------------

The accumulated MSMS spectra are analyzed by ProQuant and ProGroup software packages (Applied Biosystems) using the SwissProt database for protein identification. The ProQuant analysis was carried out with a 75% confidence cutoff with a mass deviation of 0.15 Da for the precursor and 0.1 Da for the fragment ions. The ProGroup reports were generated with a 95% confidence level for protein identification. Protein Pilot software package was used to assess the data produced from the mass spectrometry analyses. The Venn diagrams were constructed using the NIH software program (<http://ncrr.pnl.gov>). Graphic comparisons with log conversions and error bars for protein expression were produced using the ProQuant software. Descriptive statistics were performed using SPSS statistical software.

3. Results {#sec3}
==========

Tables [1](#tab1){ref-type="table"}--[5](#tab5){ref-type="table"}summarize the results of the mass spectrometry analysis of the pooled salivary specimens and illustrate protein comparisons between Stage IIa versus healthy and Stage IIb versus healthy. The results identified and compared approximately 174 differentially expressed proteins in the saliva specimens. Of the 174 proteins, 158 (91%) were significant at an alpha level of *P *\< .05 with a 95% confidence level. The mean percent peptide coverage for the complete panel proteins was 63.5% (±19.6) with a range of 35% to 96.5% coverage. The median value was 67.7% coverage.

The pie chart in [Figure 1](#fig1){ref-type="fig"}illustrates the percentage of proteins according to protein function. There were 55 proteins that were common to both cancer stages in comparison to each other while there were 20 proteins unique to Stage IIa and 28 proteins that were unique to Stage IIb ([Table 1](#tab1){ref-type="table"}).

[Figure 2](#fig2){ref-type="fig"}represents a Venn diagram of the overlapping proteins between the three groups of women.[Figure 3](#fig3){ref-type="fig"}illustrates the comparison of the log ratio of the relative intensity (cancer/control) of the proteins which were common to both Stage IIa and Stage IIb while [Figure 4](#fig4){ref-type="fig"}shows the proteins that were different between the two groups. It is worth noting that in [Figure 3](#fig3){ref-type="fig"}the stage IIb protein ratios ($\overline{X}1.675$; ±0.471) are greater than the stage IIa ratios ($\overline{X}1.431$; ±0.469) for the same proteins. Consequently, a paired *t*-test was performed comparing the two groups of values. The difference in the mean values between the two groups is greater than would be expected by chance; there is a statistically significant difference (*t* = −2.882;  *P* \< .008).

Tables [2](#tab2){ref-type="table"}and [3](#tab3){ref-type="table"}represent the up- (*n* = 34) and down- (*n* = 41) regulated proteins for the pooled saliva sample composed of individuals diagnosed with a Stage IIa IDC. The fold-increase of protein and *P*-values are also presented. As shown in Tables [2](#tab2){ref-type="table"}and [3](#tab3){ref-type="table"}, 40 of the 75 proteins (53%) were significant at the *P *\< .001 to *P *\< .0001 levels.

Tables [4](#tab4){ref-type="table"}and [5](#tab5){ref-type="table"}are a list of the up- (*n* = 38) and down- (*n* = 45) regulated proteins observed in the Stage IIb cancer as compared to healthy controls. Of these 83 differentially expressed proteins, 54 (65%) were significant at the *P *\< .001 to *P *\< .0001 levels. There were 6 proteins that exhibited a 2.0 or greater fold increase in protein level in the Stage IIb cancer cohort as compared to the control subjects.

4. Discussion {#sec4}
=============

To the best of our knowledge this is the first attempt to determine salivary protein profile alterations related to lymphovascular invasion. As a consequence we have only a few references by which to compare our data.

The proteins listed in Tables [2](#tab2){ref-type="table"}--[4](#tab4){ref-type="table"}are common to saliva and are listed in references concerning salivary proteomics of whole saliva and those constituents contributed by individual gland secretions \[[@B23], [@B32]--[@B35]\]. Likewise, many of the proteins are common to those identified in proteomic studies of cancer cell lines and serum or plasma from individuals diagnosed with IDC \[[@B23], [@B24], [@B36]--[@B40]\]. Additionally, there is a proteomic study by Pei et al. \[[@B42]\] that compared proteomic tissue protein profiles from paired normal tissue to malignant tissues with and without lymphovascular invasion \[[@B42]\]. Their results yielded 25 differentially expressed proteins among node positive and node negative, adenocarcinoma, colorectal cancer patients. From the list of 25 proteins that were differentially expressed when compared to a normal control by Pei et al., we matched 8 (32%) of them. These proteins were Apo-A1 protein, vimentin, cytokeratin-8, glutathione s-transferase, keratin 1, fructose-bisphosphate aldolase, alpha enolase, and transferring precursor \[[@B42]\]. Pei also reports Annexin II and IV while we found members Annexin I and III of the same family of proteins. Pei et al. identified four proteins which were differentially expressed. These were heat shock protein 27 (HSP-27), glutathione S-transferase (GST), Annexin II, and liver-fatty acid binding protein (L-FABP). The authors of this manuscript found 48 differentially expressed proteins ([Figure 4](#fig4){ref-type="fig"}) which included GST and a family member of the fatty acid binding proteins, epidermal-fatty acid binding protein.

A second by Li et al. \[[@B43]\] used metastatic (lymph nodes) breast cancer cell lines that they developed in order to produce protein profile comparisons \[[@B43]\]. Comparative proteomic analysis using 2-DE and LC-IT-MS revealed that 102 protein gel spots were altered more than three-fold between the variant and its parental counterpart. Using SEQUEST with uninterpreted tandem mass raw data, they found eleven differentially expressed protein spots that were identified with high confidence. The proteins were identified as Cathepsin D precursor, peroxiredoxin 6 (PDX6), heat shock protein 27 (HSP27), HSP60, tropomyosin 1 (sent in the highly metastatic variant, whereas alpha B-crystalline (CRAB) was only detected in its parTPM1), TPM2, TPM3, TPM4, 14-3-3 protein epsilon, and tumor protein D54. The proteins were preental counterpart \[[@B43]\]. As shown in Tables [2](#tab2){ref-type="table"}--[5](#tab5){ref-type="table"}, we identified a number of the same proteins. For example, the 14-3-3, tropomyosin and the peroxiredoxin family of proteins were found to be altered in the saliva of our late stage cancer profiles as well. Of particular interest is the fact that these proteins were not altered in the profiles of early stage cancer, that is, Stage 0 and Stage I performed by the authors of this manuscript \[[@B23], [@B44]\].

5. Conclusions {#sec5}
==============

The authors have examined the salivary proteome that is altered in the presence of carcinoma of the breast with and without lymph node metastasis. We do not want to over emphasize the findings at this point, but we are encouraged to find that these protein profiles are found to be altered in the supernants from cancer tissues which provide additional support to our findings.

The authors urge the exploration of saliva proteomics for in vivo systems modeling of carcinoma of tissues of ectodermal origin. Saliva can also be described as a media which provides "real-time" results \[[@B45]\]. The fluid is continually produced and excreted in an open-ended circuit, unlike blood which exists in a "closed-loop." Blood, a circulating media, may contain proteins that are a day, a week, or a month old as well as proteins which have passed numerous times through many organ systems or have been excreted \[[@B45]\]. Saliva, with its continuous flow, is not subject to the aforementioned effects. Consequently, saliva and nipple aspirates may be a more useful than blood as the protein profiles of these fluids easier to assay than blood and are both altered in the presence of malignant diseases \[[@B18], [@B45]\].

Further study is required to determine their diagnostic utility. The authors plan to validate the protein biomarkers by western blot using commercially available antibodies. ELISA will also be used to assay a larger sample size and determine the sensitivity and specificity of the biomarkers. It is the hope of the investigators that this preliminary research will establish the foundation for a "point-of-care" test for clinical decision making in the treatment of carcinoma of the breast.

6. Disclosure Statement {#sec6}
=======================
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  Summary of protein expression profiles                                   
  ---------------------------------------- -------------- ---------------- ---------------
  Comparison                               Up Regulated   Down Regulated   Total Markers
  Stage IIa versus                         34             41               75
  healthy                                                                  
  Stage IIb versus                         38             45               83
  healthy                                                                  
  Totals                                   72             86               158
                                                                           
  Stage IIa compared to stage IIb                                          
                                                                           
  Common proteins                          24             31               55
  Differing proteins                       24             24               48
  Totals                                   48             55               83

###### 

Upregulated salivary proteins for stage IIa (*n* = 34).

  Accession   Gene ID   Name                                                                   Ratio    *P* value
  ----------- --------- ---------------------------------------------------------------------- -------- -----------
  P02763      A1AG1     Alpha-1 acid glycoprotein 1 precursor (AGP 1)                          1.3229   .0127
  P01023      A2MG      Alpha-2 macroglobulin precursor                                        1.1446   .0324
  P07108      ACBP      AcylCoA binding protein                                                1.2264   .0254
  P02768      ALBU      Serum albumin precursor                                                1.3677   .0000
  P04745      AMYS      Salivary alpha amylase precursor                                       1.3564   .0000
  P61769      B2MG      Beta-2 microglobulin precursor                                         1.1463   .0465
  P04040      CATA      Catalase                                                               1.0918   .0183
  P01024      CO3       Complement C3 precursor                                                1.1698   .0194
  P01040      CYTA      CystatinA (StefinA) (CystatinAS)                                       1.4403   .0005
  P04080      CYTB      CystatinB (StefinB)                                                    1.1440   .0108
  P06733      ENOA      Alphaenolase                                                           1.2626   .0000
  Q01469      FABPE     Fatty acidbinding protein, epidermal (EFABP)                           1.3126   .0022
  Q5VTM1      fAM25     Protein FAM25                                                          1.3647   .0165
  P02765      FETUA     Alpha-2HS glycoprotein precursor                                       1.3101   .0129
  P00738      HPT       Haptoglobin precursor                                                  1.5562   .0000
  P01781      HV320     Ig heavy chain VIII region GAL                                         1.3879   .0336
  P01876      IGHA1     Ig alpha1 chain C region                                               1.4641   .0000
  P01591      IGJ       Immunoglobulin J chain                                                 1.2429   .0002
  P35527      K1C9      Keratin, type I cytoskeletal 9                                         1.1629   .0279
  P01834      KAC       Ig kappa chain C region                                                1.0953   .0016
  P06870      KLK1      Kallikrein1 precursor                                                  1.6991   .0000
  P06309      KV205     Ig kappa chain VII region GM607 precursor                              1.2300   .0131
  P18135      KV312     Ig kappa chain VIII region HAH precursor                               1.2637   .0077
  P01842      LAC       Ig lambda chain C regions                                              1.0933   .0004
  P31025      LCN1      Lipocalin1 precursor                                                   1.3213   .0000
  P80188      NGAL      Neutrophil gelatinase associated lipocalin precursor (Oncogene 24p3)   1.5325   .0000
  P01833      PIGR      Hepatocellular carcinomaassociated protein TB6                         1.3233   .0000
  P26447      S10A4     Protein S100A4 (S100 calciumbinding protein A4)                        1.1539   .0027
  P31151      S10A7     Protein S100A7 (Psoriasin)                                             3.3466   .0000
  P35321      SPR1A     Cornifin-A (19 kDa pancornulin)                                        1.4452   .0093
  Q9UBC9      SPRR3     Cornifin beta (22 kDa pancornulin)                                     1.2787   .0000
  P20061      TCO1      Transcobalamin1 precursor                                              1.1222   .0383
  P62328      TYB4      Thymosin beta 4                                                        2.1483   .0007
  P62988      UBIQ      Ubiquitin                                                              1.3427   .0424

###### 

Downregulated salivary proteins for stage IIa (*n* = 41).

  Accession   Gene ID   Name                                                                       Ratio    *P* value
  ----------- --------- -------------------------------------------------------------------------- -------- -----------
  P31947      1433S     14-3-3 protein sigma (Epithelial cell marker protein 1)                    0.7921   .0043
  P04075      ALDOA     Fructose-bisphosphate aldolase                                             0.7036   .0000
  Q8N4F0      BPIL1     Lung and nasal epith, carcinoma-assoc. protein 2                           0.7465   .0002
  P23280      CAH6      Carbonic anhydrase 6 precursoranhydrase                                    0.7871   .0000
  P54108      CRIS3     Cysteine-rich secretory protein 3 precursor (CRISP-3)                      0.7846   .0003
  P01034      CYTC      Cystatin-C precursor (Cystatin-3)                                          0.7108   .0000
  P28325      CYTD      Cystatin-D precursor (Cystatin-5)                                          0.6047   .0000
  P01037      CYTN      Cystatin-SN precursor                                                      0.3200   .0000
  P01036      CYTS      Cystatin-S precursor (Cystatin-4)                                          0.3385   .0000
  P09228      CYTT      Cystatin-SA precursor (Cystatin-S5)                                        0.4153   .0000
  Q9UGM3      DMBT1     Deleted in malignant brain tumors 1 protein precursor (Glycoprotein 340)   0.7910   .0050
  P02671      FIBA      Fibrinogen alpha chain precursor \[Contains: Fibrinopeptide A\]            0.8964   .0104
  P09211      GSTP1     Glutathione S-transferase P                                                0.8782   .0261
  Q8IUE6      H2A2B     Histone H2A                                                                0.5435   .0211
  Q99880      H2B1L     Histone H2B type 1-L                                                       0.5576   .0008
  P62805      H4        Histone H4                                                                 0.4195   .0000
  P15515      HIS1      Histatin-1 precursor                                                       0.3152   .0340
  P01857      IGHG1     Ig gamma-1 chain C region                                                  0.9173   .0306
  P13646      K1C13     Keratin, type I cytoskeletal 13 (Cytokeratin-13)                           0.6395   .0011
  P08779      K1C16     Keratin, type I cytoskeletal 16 (Cytokeratin-16)                           0.6220   .0001
  P61626      LYSC      Lysozyme C precursor                                                       0.4121   .0000
  P01871      MUC       Ig mu chain C region                                                       0.6877   .0000
  Q9HC84      MUC5B     Mucin-5B precursor                                                         0.6404   .0000
  P80303      NUCB2     Nucleobindin-2 precursor (Gastric cancer antigen Zg4)                      0.6836   .0000
  P22079      PERL      Lactoperoxidase precursor                                                  0.8196   .0000
  P05164      PERM      Myeloperoxidase precursor                                                  0.6894   .0000
  P12273      PIP       Prolactin-inducible protein precursor                                      0.6382   .0000
  P23284      PPIB      Peptidyl-prolyl cis-trans isomerase B precursor                            0.8769   .0326
  P02812      PRB2      Basic salivary proline-rich protein 2                                      0.5422   .0000
  Q06830      PRDX1     Peroxiredoxin-1                                                            0.7296   .0020
  P02810      PRPC      Salivary acidic proline-rich phosphoprotein 1/2 precursor                  0.8848   .0000
  P06703      S10A6     Protein S100-A6 (Growth factor-inducible protein 2A9)                      0.8926   .0051
  P05109      S10A8     Protein S100-A8 (S100 calcium-binding protein A8)                          0.5888   .0000
  P06702      S10A9     Protein S100-A9 (S100 calcium-binding protein A9)                          0.6622   .0000
  P31949      S10AB     Protein S100-A11 (S100 calcium-binding protein A11)                        0.6526   .0017
  Q96DR5      SPLC2     Lung and nasal epith. carcinoma-assoc. protein 2 precursor                 0.3270   .0000
  Q08188      TGM3      Protein-glutamine gamma-glutamyltransferase E precursor                    0.7454   .0168
  P29401      TKT       Transketolase                                                              0.8236   .0351
  P06753      TPM3      Tropomyosin alpha-3 chain                                                  0.7809   .0016
  P02788      TRFL      Lactotransferrin precursor                                                 0.8118   .0000
  P08670      VIME      Vimentin                                                                   0.7728   .0190

###### 

Upregulated salivary proteins for stage IIb (*n* = 38).

  Accession   Gene ID   Name                                                               Ratio    *P* value
  ----------- --------- ------------------------------------------------------------------ -------- -----------
  P02763      A1AG1     Alpha-1-acid glycoprotein 1 precursor (AGP 1)                      1.8128   .0003
  P01023      A2MG      Alpha-2-macroglobulin precursor (Alpha-2-M)                        1.7279   .0000
  P02768      ALBU      Serum albumin precursor                                            1.9149   .0000
  P12429      ANXA3     Annexin A3 (Annexin III)                                           1.3144   .0058
  P02647      APOA1     Apolipoprotein A-I precursor (Apo-AI)                              1.2233   .0012
  P00915      CAH1      Carbonic anhydrase 1                                               3.3424   .0356
  P62158      CALM      Calmodulin (CaM)                                                   1.5783   .0391
  P04040      CATA      Catalase                                                           1.4806   .0007
  P01024      CO3       Complement C3 precursor                                            1.3391   .0000
  P06733      ENOA      Alpha-enolase                                                      1.4856   .0000
  P02765      FETUA     Alpha-2-HS-glycoprotein precursor (Fetuin-A)                       1.4004   .0007
  P52566      GDIS      Rho GDP-dissociation inhibitor 2 (Rho GDI 2)                       1.3866   .0046
  P69905      HBA       Hemoglobin subunit alpha (Hemoglobin alpha chain)                  1.8916   .0000
  P68871      HBB       Hemoglobin subunit beta (Hemoglobin beta chain)                    1.8326   .0000
  P02790      HEMO      Hemopexin precursor (Beta-1B-glycoprotein)                         2.2691   .0001
  P00738      HPT       Haptoglobin precursor                                              2.3331   .0000
  P01762      HV301     Ig heavy chain V-III region TRO                                    1.3350   .0262
  P01781      HV320     Ig heavy chain V-III region GAL                                    1.6357   .0259
  P01876      IGHA1     Ig alpha-1 chain C region                                          1.4384   .0000
  P01877      IGHA2     Ig alpha-2 chain C region                                          1.1678   .0288
  P01857      IGHG1     Ig gamma-1 chain C region                                          1.4955   .0000
  P01859      IGHG2     Ig gamma-2 chain C region                                          1.5578   .0000
  P01591      IGJ       Immunoglobulin J chain                                             1.3564   .0000
  P01834      KAC       Ig kappa chain C region                                            1.2156   .0000
  P06870      KLK1      Kallikrein-1 precursor                                             1.6222   .0000
  P18135      KV312     Ig kappa chain V-III region HAH precursor                          1.4020   .0009
  P01842      LAC       Ig lambda chain C regions                                          1.3162   .0000
  P31025      LCN1      Lipocalin-1 precursor                                              2.1725   .0000
  P80188      NGAL      Neutrophil gelatinase-assoc. lipocalin precursor (Oncogene 24p3)   1.6181   .0000
  P01833      PIGR      Hepatocellular carcinoma-associated protein TB6                    1.2753   .0000
  P31151      S10A7     Protein S100-A7 (S100 calcium-binding protein A7)                  2.2683   .0000
  P35321      SPR1A     Cornifin-A(SPR-IA)                                                 1.6742   .0084
  Q9UBC9      SPRR3     Cornifin beta (22 kDa pancornulin)                                 1.5506   .0000
  P37837      TALDO     Transaldolase                                                      1.3811   .0053
  P20061      TCO1      Transcobalamin-1 precursor (Transcobalamin I)                      1.2262   .0001
  P02787      TRFE      Serotransferrin precursor (Transferrin)                            1.5744   .0000
  P62328      TYB4      Thymosin beta-4 (T beta 4)                                         3.3412   .0003
  P62988      UBIQ      Ubiquitin                                                          1.5925   .0055

###### 

Downregulated salivary proteins for stage IIb (*n* = 45).

  Accession   Gene ID   Protein Name                                                              Ratio    *P* value
  ----------- --------- ------------------------------------------------------------------------- -------- -----------
  P31947      1433S     14-3-3 protein sigma (Stratifin) (Epithelial cell marker protein 1)       0.5486   .0000
  P63104      1433Z     14-3-3 protein zeta/delta (Protein kinase C inhibitor protein 1)          0.5718   .0378
  P04075      ALDOA     Fructose-bisphosphate aldolase A (Lung cancer antigen NY-LU-1)            0.7080   .0001
  P19961      AMYC      Alpha-amylase 2B precursor                                                0.6840   .0020
  P04745      AMYS      Salivary alpha-amylase precursor                                          0.9302   .0042
  P04083      ANXA1     Annexin A1 (p35)                                                          0.8105   .0080
  P23280      CAH6      Carbonic anhydrase 6 precursor                                            0.4900   .0000
  P10909      CLUS      Clusterin precursor (Complement-associated protein SP-40,40)              0.7704   .0252
  P04080      CYTB      Cystatin-B (Stefin-B) (Liver thiol proteinase inhibitor)                  0.8705   .0007
  P01034      CYTC      Cystatin-C precursor (Cystatin-3)                                         0.5621   .0000
  P28325      CYTD      Cystatin-D precursor (Cystatin-5)                                         0.4856   .0000
  P01037      CYTN      Cystatin-SN precursor (Cystatin-1)                                        0.2323   .0000
  P01036      CYTS      Cystatin-S precursor (Cystatin-4)                                         0.2437   .0000
  P09228      CYTT      Cystatin-SA precursor (Cystatin-S5)                                       0.3033   .0000
  Q02487      DSC2      Desmocollin-2 precursor (Desmosomal glycoprotein II and III)              0.7029   .0063
  P06744      G6PI      Glucose-6-phosphate isomerase (SA-36)---(Human)                           0.5118   .0013
  P09211      GSTP1     Glutathione S-transferase P                                               0.7563   .0001
  Q8IUE6      H2A2B     Histone H2A type 2-B                                                      0.5699   .0058
  Q99880      H2B1L     Histone H2B type 1-L (H2B.c)                                              0.6841   .0373
  P62805      H4        Histone H4                                                                0.3745   .0000
  P15515      HIS1      Histatin-1 precursor (Histidine-rich protein 1)                           0.2237   .0032
  P30740      ILEU      Leukocyte elastase inhibitor (Serpin B1)                                  0.9203   .0418
  P13646      K1C13     Keratin, type I cytoskeletal 13 (Cytokeratin-13)                          0.4247   .0000
  P08779      K1C16     Keratin, type I cytoskeletal 16 (Cytokeratin-16)                          0.4900   .0000
  P02538      K2C6A     Keratin, type II cytoskeletal 6A (Cytokeratin-6A)                         0.6744   .0019
  P61626      LYSC      Lysozyme C precursor                                                      0.6646   .0000
  P01871      MUC       Ig mu chain C region                                                      0.7992   .0000
  Q9HC84      MUC5B     Mucin-5B precursor (Mucin-5 subtype B, tracheobronchial)                  0.9357   .0260
  P80303      NUCB2     Nucleobindin-2 precursor (Gastric cancer antigen Zg4)                     0.4934   .0000
  P07237      PDIA1     Protein disulfide-isomerase precursor (p55)                               0.8132   .0205
  P22079      PERL      Lactoperoxidase precursor                                                 0.6879   .0000
  P05164      PERM      Myeloperoxidase precursor                                                 0.7856   .0049
  P12273      PIP       Prolactin-inducible protein precursor (gp17)                              0.4659   .0000
  P62937      PPIA      Peptidyl-prolyl cis-trans isomerase A                                     0.8031   .0091
  P23284      PPIB      Peptidyl-prolyl cis-trans isomerase B precursor                           0.7089   .0006
  P02812      PRB2      Basic salivary proline-rich protein 2 (Salivary proline-rich protein)     0.4204   .0000
  Q06830      PRDX1     Peroxiredoxin-1                                                           0.6877   .0006
  P02810      PRPC      Salivary acidic proline-rich phosphoprotein 1/2 precursor (PRP-1/PRP-2)   0.6861   .0000
  P05109      S10A8     Protein S100-A8 (S100 calcium-binding protein A8) (Calgranulin-A)         0.8042   .0000
  Q96DR5      SPLC2     Lung and nasal epith. carcinoma-assoc. protein 2 precursor                0.2322   .0000
  P10599      THIO      Thioredoxin (Trx) (ATL-derived factor)                                    0.8003   .0003
  P06753      TPM3      Tropomyosin alpha-3 chain (Tropomyosin-3)                                 0.8990   .0215
  P02788      TRFL      Lactotransferrin precursor                                                0.7072   .0000
  P08670      VIME      Vimentin                                                                  0.7717   .0277
  P25311      ZA2G      Zinc-alpha-2-glycoprotein precursor (Zn-alpha-2-glycoprotein)             0.8543   .0000

[^1]: Recommended by Sofia D. Merajver
